1. Home
  2. CADL vs XOMAP Comparison

CADL vs XOMAP Comparison

Compare CADL & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CADL
  • XOMAP
  • Stock Information
  • Founded
  • CADL 1999
  • XOMAP N/A
  • Country
  • CADL United States
  • XOMAP United States
  • Employees
  • CADL N/A
  • XOMAP 13
  • Industry
  • CADL Biotechnology: Pharmaceutical Preparations
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • Sector
  • CADL Health Care
  • XOMAP Health Care
  • Exchange
  • CADL Nasdaq
  • XOMAP Nasdaq
  • Market Cap
  • CADL 185.2M
  • XOMAP N/A
  • IPO Year
  • CADL 2021
  • XOMAP N/A
  • Fundamental
  • Price
  • CADL $6.20
  • XOMAP $25.42
  • Analyst Decision
  • CADL Strong Buy
  • XOMAP
  • Analyst Count
  • CADL 1
  • XOMAP 0
  • Target Price
  • CADL $11.00
  • XOMAP N/A
  • AVG Volume (30 Days)
  • CADL 599.6K
  • XOMAP N/A
  • Earning Date
  • CADL 08-08-2024
  • XOMAP N/A
  • Dividend Yield
  • CADL N/A
  • XOMAP N/A
  • EPS Growth
  • CADL N/A
  • XOMAP N/A
  • EPS
  • CADL N/A
  • XOMAP N/A
  • Revenue
  • CADL N/A
  • XOMAP N/A
  • Revenue This Year
  • CADL N/A
  • XOMAP N/A
  • Revenue Next Year
  • CADL N/A
  • XOMAP N/A
  • P/E Ratio
  • CADL N/A
  • XOMAP N/A
  • Revenue Growth
  • CADL N/A
  • XOMAP N/A
  • 52 Week Low
  • CADL $0.66
  • XOMAP N/A
  • 52 Week High
  • CADL $14.30
  • XOMAP N/A
  • Technical
  • Relative Strength Index (RSI)
  • CADL 45.08
  • XOMAP 47.85
  • Support Level
  • CADL $5.75
  • XOMAP $25.32
  • Resistance Level
  • CADL $7.34
  • XOMAP $25.90
  • Average True Range (ATR)
  • CADL 0.50
  • XOMAP 0.37
  • MACD
  • CADL 0.12
  • XOMAP -0.06
  • Stochastic Oscillator
  • CADL 33.47
  • XOMAP 21.50

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: